在韩国对Vi荚膜多糖疫苗的免疫原性进行了为期三年的评估。
Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
作者信息
Kim Y R, Yoo J H, Hur J K, Kang J H, Shin W S, Kang M W
机构信息
Department of Internal Medicine and Pediatrics, Catholic University Medical College, Seoul, Korea.
出版信息
J Korean Med Sci. 1995 Oct;10(5):314-7. doi: 10.3346/jkms.1995.10.5.314.
The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.
对单剂量伤寒沙门氏菌Vi荚膜多糖（CPS）疫苗接种前及接种后1、3、12和36个月的免疫原性进行了评估。85名成年人（20 - 28岁）和64名儿童（8 - 16岁）肌肉注射单剂量25微克Vi CPS疫苗，并通过被动血凝试验检测Vi CPS抗体滴度。149名接种者中，138名（92.6%）在接种后1个月出现血清转化，随后141名中的138名（97.9%）在3个月时出现血清转化。137名接种者中，116名（84.7%）在接种后12个月Vi抗体滴度持续上升，100名中的55名（55.0%）在36个月时抗体滴度升高4倍或更高。未观察到明显不良反应。接种疫苗3 - 5年后可能需要加强注射。
Zotero 插件